Latest News in the pharma Industry
Research & Development
FDA accepts BLA for avelumab for the treatment of metastatic urothelial carcinoma for Priority Review
28 Feb 2017
Second Biologics License Application accepted by the FDA for avelumab.
Read more
CHMP recommends EU Conditional Marketing Authorisation for Natpar for patients with chronic hypoparathyroidism
27 Feb 2017
If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the management of chronic hypoparathyroidism, the only endocrine-deficiency disorder with no hormone treatment.
Read more
Real-world data show lower risk of stroke and major bleeding for Pradaxa compared with warfarin
26 Feb 2017
Compared with warfarin, Pradaxa was associated with a 26% reduced risk of stroke and a 20% reduced risk of major bleeding.
Read more
SGS platform provides modeling and simulation solutions for clinical trials
23 Feb 2017
Tool explores the time course of drug exposure, biomarker response and outcome.
Read more
Updated Phase I Data show Bavarian Nordic's vaccine candidate induces broad and durable immune response against RSV
23 Feb 2017
Antibody levels maintained against multiple targets 6 months post vaccination.
Read more
NIH begins study of vaccine to protect against mosquito-borne diseases
22 Feb 2017
Experimental vaccine targets mosquito saliva.
Read more
Cell lines and media for difficult to culture tumour types
22 Feb 2017
Aids R&D initiatives to advance precision medicine.
Read more
Can yeast rise to the challenge of curing cancer?
21 Feb 2017
Modified baker’s yeasts cause an immune response and the production of lymphocyte killers, which detect and eliminate cancerous cells.
Read more.jpg)
Innova Biosciences introduces Magnetic Conjugation Kit
21 Feb 2017
New kit enables covalent conjugation of antibodies and proteins to magnetic particles.
Read more
New data in Crohn’s disease patients shows similar efficacy and safety profiles for Inflectra and Remicade
20 Feb 2017
Trial data further supports the existing clinical profile of CT-P13 in inflammatory bowel disease.
Read more
Phase II study supports potential for Genentech’s Tecentriq plus Avastin for people with mRCC
19 Feb 2017
Study showed that people whose disease expressed PD-L1 and were treated with Tecentriq plus Avastin had a 36% reduction in the risk of their disease worsening
Read more
FDA expands approval of Spiriva Respimat inhalation spray
16 Feb 2017
Steroid-free Spiriva Respimat now approved as asthma treatment for age 6 and older.
Read more